Financial reports
20-F
2022 FY
Annual report (foreign)
22 Mar 23
20-F
2021 FY
Annual report (foreign)
30 Mar 22
20-F/A
2020 FY
Annual report (foreign) (amended)
19 May 21
20-F
2020 FY
Annual report (foreign)
15 Mar 21
20-F
2019 FY
Annual report (foreign)
12 Mar 20
20-F
2018 FY
Annual report (foreign)
11 Mar 19
20-F
2017 FY
Annual report (foreign)
15 Mar 18
20-F/A
2016 FY
Annual report (foreign) (amended)
3 Apr 17
20-F
2016 FY
Annual report (foreign)
30 Mar 17
20-F
2015 FY
Annual report (foreign)
31 Mar 16
Current reports
6-K
Report of Foreign Private Issuer
2 Apr 24
6-K/A
Extraordinary General Meeting of Shareholders
21 Mar 24
6-K
Extraordinary General Meeting of Shareholders
21 Mar 24
6-K
XTL To Aquire The Social Proxy
20 Mar 24
6-K
Report of Foreign Private Issuer
15 Nov 23
6-K
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
20 Oct 23
6-K
Report of Foreign Private Issuer
10 Aug 23
6-K
Report of Foreign Private Issuer
16 May 23
6-K
Current report (foreign)
2 Mar 23
6-K
Current report (foreign)
23 Feb 23
Registration and prospectus
424B3
Prospectus supplement
9 Jun 21
POS AM
Prospectus update (post-effective amendment)
2 Jun 21
424B3
Prospectus supplement
7 Mar 18
F-1/A
Registration statement (foreign) (amended)
28 Feb 18
F-1/A
Registration statement (foreign) (amended)
1 Feb 18
D
$2.8M in equity / options / securities to be acquired, sold $2.8M, 22 investors
29 Mar 17
D
$2.5M in options / securities to be acquired, sold $2.5M, 5 investors
1 Mar 17
424B5
Prospectus supplement for primary offering
22 Feb 17
F-1/A
Registration statement (foreign) (amended)
8 Nov 16
F-1
Registration statement (foreign)
31 Dec 15
Proxies
No filings
Other
EFFECT
Notice of effectiveness
8 Jun 21
EFFECT
Notice of effectiveness
6 Mar 18
CORRESP
Correspondence with SEC
2 Mar 18
CORRESP
Correspondence with SEC
7 Nov 16
UPLOAD
Letter from SEC
26 Jan 16
EFFECT
Notice of effectiveness
4 Apr 14
CORRESP
Correspondence with SEC
3 Apr 14
CORRESP
Correspondence with SEC
2 Apr 14
CORRESP
Correspondence with SEC
2 Apr 14
UPLOAD
Letter from SEC
17 Mar 14